London-based drug firm has entered into a new field of developing drugs using proteins secreted by the cells called as “Secretome”.
New Drug to Fight Alzheimer's Disease Soon from AstraZeneca, Eli Lilly Combo
British drugmaker AstraZeneca and Eli Lilly of the United States announced a partnership to develop a new drug aimed at treating Alzheimer's disease the most common form of dementia.
British drugmaker AstraZeneca and Eli Lilly of the United States announced a partnership to develop a new drug aimed at treating Alzheimer's disease the most common form of dementia.
‘Secretome, proteins secreted by cells, plays a major role in most biological processes and is considered to be an invaluable source for identifying new biomarkers, drug targets and for developing novel biologics.’
Pascal Soriot, AstraZeneca chief executive, said, “We’re tremendously excited to be part of this innovative collaboration as we explore what science can do to advance medical research. Harnessing the power of the Secretome in this unprecedented way will help us to identify new biomarkers, drug targets and ultimately develop next-generation biological treatments.” The comapny said that Secretome plays a major role in most biological processes like cardiac regeneration, the maintenance of functioning cells for glucose balance, cancer proliferation and migration. This group of proteins is therefore considered to be an invaluable source for identifying new biomarkers, drug targets and for developing novel biologics.
Source-Medindia
GlaxoSmithKline and AstraZeneca Drugs Show Promise In Clinical Trials For Lupus
GSK’s phase III trials of the B-lymphocyte stimulator reduced disease activity by 61% and AZ’s phase II trials of anifrolumab reduced the activity by 51.5%.
GSK’s phase III trials of the B-lymphocyte stimulator reduced disease activity by 61% and AZ’s phase II trials of anifrolumab reduced the activity by 51.5%.
AstraZeneca Halts Combined Trials of Two Lung Cancer Drugs Due to Safety Issues
London-based drug firm has paused the tests due to an increase in the incidence of interstitial lung disease-like reports. No deaths have been reported.
London-based drug firm has paused the tests due to an increase in the incidence of interstitial lung disease-like reports. No deaths have been reported.
AstraZeneca Inks Agreement with Roche, Qiagen for New Blood-based Cancer Drug Tests
AstraZeneca has signed an agreement with Roche and Qiagen to develop two separate diagnostic tests, both using simple blood samples, to find out patients who will benefit from its lung cancer drugs
AstraZeneca has signed an agreement with Roche and Qiagen to develop two separate diagnostic tests, both using simple blood samples, to find out patients who will benefit from its lung cancer drugs
